Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 Combined With Other Therapies for Perioperative Treatment of Resectable NSCLC
NCT07863167Phase 2Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ruzaltatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07863167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863167.